Dr Bernadett Szabados is a clinical research fellow at Barts Cancer Institute, London, UK. She trained in several European centers including Brussels, Belgium and Munich, Germany, having had an earlier career in urology, now continuing a thesis in translational oncology.

Her specialist interests are focused on urological malignancies including but not limited to renal- and transitional cell carcinoma with  the goal of individualizing  and improving care and treatment.

Her interests span from basic laboratory research to clinical trials.

She participated in over 10 international, randomized, phase 3 trials and  involved in the process leading to the regulatory approval of axitinib/pembrolizumab in kidney cancer.